In the News

A comprehensive review of idiopathic multicentric Castleman disease (iMCD) with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) cases has led researchers to establish a validated definition for the disease.

The findings are published in...

Uveitis relapses are common among patients with juvenile idiopathic arthritis (JIA) who stop treatment with disease-modifying antirheumatic drugs (DMARDs), according to a study presented at the Virtual 2021 Annual Meeting of the European League Against Rheumatism (EULAR).

Patients who...

The US Food and Drug Administration (FDA) is alerting the public that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with the rheumatoid arthritis (RA) and ulcerative colitis drug tofacitinib (Xeljanz, Xeljanz XR), compared...

Patients with rheumatoid arthritis (RA) may benefit from treatment with monoclonal antibody otilimab, according to a study published in The Lancet Rheumatology.

In a multicentre, dose-ranging study, Christopher D. Buckley, University of Birmingham, Birmingham, United Kingdom, and...

The American College of Rheumatology has published new guidelines for treating and managing systemic juvenile idiopathic arthritis (JIA), oligoarthritis, and temporomandibular joint (TMJ) arthritis.

“Our overarching goal with the update project, including part 1 in 2019 and this current...

The American College of Rheumatology (ACR) has updated its guideline for the management of rheumatoid arthritis (RA).

The new guideline, presented at the 2020 Virtual ACR Meeting was developed by a broad range of stakeholders in RA treatment, including rheumatologists, methodologists, and...

Measuring levels of certain small molecules produced from essential fatty acids in a person’s blood that are involved in regulating inflammation can help predict which patients with rheumatoid arthritis (RA) will respond to treatment with disease-modifying antirheumatic drugs (DMARDs), according...

By Denise Baez

NEW YORK -- October 15, 2020 -- Patients with autoimmune diseases appear to have an increased risk of coronavirus disease 2019 (COVID-19), primarily attributed to glucocorticoid use, although their clinical outcomes were not considerably worse when compared with individuals...

The US Food and Drug Administration (FDA) approved burosumab-twza (Crysvita) injection to treat patients aged 2 years and older with tumour-induced osteomalacia (TIO).

“Treatment for TIO focuses on identifying and removing the tumour that causes the disease; however, when that is not...

The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) injection for the treatment of active Still’s Disease, including adult-onset Still’s Disease (AOSD).

“Prior to today’s approval, patients had no FDA-approved treatments for their disease, which can include...

Pages